{
    "nctId": "NCT00322348",
    "briefTitle": "Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women",
    "officialTitle": "An Open-label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 98,
    "primaryOutcomeMeasure": "Percentage of Participants With Progression Free Survival (PFS) at Week 24",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pre-menopausal women aged 18 years or over with histologically/cytologically-confirmed oestrogen receptor positive (ER +ve) breast cancer\n* World Health Organization (WHO) performance status of 0, 1, or 2\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Treatment with tamoxifen or other hormonal therapies as early breast cancer (EBC) adjuvant in the previous 24 weeks\n* Received radiotherapy within the past 4 weeks\n* History of systemic malignancy other than breast cancer within the previous 3 years\n* Estimated survival less than 24 weeks",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}